Home » Stocks » Oric Pharmaceuticals

Oric Pharmaceuticals Inc. (ORIC)

Stock Price: $19.76 USD 0.26 (1.33%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
After-hours: $19.90 +0.14 (0.71%) Sep 25, 6:49 PM

Stock Price Chart

Key Info

Market Cap 591.93M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 29.96M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 25, 2020
Last Price $19.76
Previous Close $19.50
Change ($) 0.26
Change (%) 1.33%
Day's Open 19.28
Day's Range 19.26 - 20.45
Day's Volume 50,032
52-Week Range 18.60 - 40.67

More Stats

Market Cap 591.93M
Enterprise Value 395.29M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 29.96M
Float 19.88M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.19M
Short Ratio 24.48
Short % of Float 15.14%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.05
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 196.64M
Net Cash / Share 6.56
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -25.36%
ROE -41.10%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$43.71*
(121.20% upside)
Low
35.0
Current: $19.76
High
52.0
Target: 43.71
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue--
Operating Income-28.57-22.37
Net Income-26.88-21.36
Shares Outstanding1.901.73
Earnings Per Share-14.15-12.32
Operating Cash Flow-23.53-20.68
Capital Expenditures-0.77-0.53
Free Cash Flow-24.30-21.21
Cash & Equivalents89.1642.64
Net Cash / Debt89.1642.64
Assets94.0946.73
Liabilities6.123.89
Book Value-90.08-64.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Oric Pharmaceuticals Inc.
Country United States
Employees 58
CEO Jacob M. Chacko

Stock Information

Ticker Symbol ORIC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ORIC
IPO Date April 24, 2020

Description

ORIC Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.